

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM844202

|                                                                                                                                                                                                 |                                             |                         |                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|-------------------------|------------------------------------------------|
| <b>SUBMISSION TYPE:</b>                                                                                                                                                                         | NEW ASSIGNMENT                              |                         |                                                |
| <b>NATURE OF CONVEYANCE:</b>                                                                                                                                                                    | RELEASE OF SECURITY INTEREST                |                         |                                                |
| <b>CONVEYING PARTY DATA</b>                                                                                                                                                                     |                                             |                         |                                                |
| <b>Name</b>                                                                                                                                                                                     | <b>Formerly</b>                             | <b>Execution Date</b>   | <b>Entity Type</b>                             |
| CITIBANK, N.A.                                                                                                                                                                                  |                                             | 10/06/2023              | National Banking Association:<br>UNITED STATES |
| <b>RECEIVING PARTY DATA</b>                                                                                                                                                                     |                                             |                         |                                                |
| <b>Name:</b>                                                                                                                                                                                    | Horizon Therapeutics USA, Inc.              |                         |                                                |
| <b>Street Address:</b>                                                                                                                                                                          | 1 Horizon Way                               |                         |                                                |
| <b>City:</b>                                                                                                                                                                                    | Deerfield                                   |                         |                                                |
| <b>State/Country:</b>                                                                                                                                                                           | ILLINOIS                                    |                         |                                                |
| <b>Postal Code:</b>                                                                                                                                                                             | 60015                                       |                         |                                                |
| <b>Entity Type:</b>                                                                                                                                                                             | Corporation: DELAWARE                       |                         |                                                |
| <b>PROPERTY NUMBERS Total: 6</b>                                                                                                                                                                |                                             |                         |                                                |
| <b>Property Type</b>                                                                                                                                                                            | <b>Number</b>                               | <b>Word Mark</b>        |                                                |
| <b>Registration Number:</b>                                                                                                                                                                     | 4833793                                     | CREALTA                 |                                                |
| <b>Serial Number:</b>                                                                                                                                                                           | 86067833                                    | CREALTA                 |                                                |
| <b>Serial Number:</b>                                                                                                                                                                           | 86067863                                    | CREALTA PHARMACEUTICALS |                                                |
| <b>Registration Number:</b>                                                                                                                                                                     | 4823992                                     | CREALTA PHARMACEUTICALS |                                                |
| <b>Registration Number:</b>                                                                                                                                                                     | 3920201                                     | KRYSTEXXA               |                                                |
| <b>Registration Number:</b>                                                                                                                                                                     | 1508914                                     | MIGERGOT                |                                                |
| <b>CORRESPONDENCE DATA</b>                                                                                                                                                                      |                                             |                         |                                                |
| <b>Fax Number:</b>                                                                                                                                                                              | 2122919868                                  |                         |                                                |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                                             |                         |                                                |
| <b>Phone:</b>                                                                                                                                                                                   | (212) 558-4229                              |                         |                                                |
| <b>Email:</b>                                                                                                                                                                                   | demarcor@sullcrom.com, nguyenb@sullcrom.com |                         |                                                |
| <b>Correspondent Name:</b>                                                                                                                                                                      | Raffaele A. DeMarco                         |                         |                                                |
| <b>Address Line 1:</b>                                                                                                                                                                          | 125 Broad Street                            |                         |                                                |
| <b>Address Line 2:</b>                                                                                                                                                                          | Sullivan & Cromwell LLP                     |                         |                                                |
| <b>Address Line 4:</b>                                                                                                                                                                          | New York, NEW YORK 10004                    |                         |                                                |
| <b>ATTORNEY DOCKET NUMBER:</b>                                                                                                                                                                  | 019095.00083 (RAD)                          |                         |                                                |
| <b>NAME OF SUBMITTER:</b>                                                                                                                                                                       | Raffaele A. DeMarco                         |                         |                                                |
| <b>SIGNATURE:</b>                                                                                                                                                                               | /Raffaele A. DeMarco/                       |                         |                                                |

OP \$165.00 4833793

|                     |            |
|---------------------|------------|
| <b>DATE SIGNED:</b> | 10/06/2023 |
|---------------------|------------|

**Total Attachments: 5**

source=Horizon- Trademark Release (March 2016 TSA) (Agreed Form)#page1.tif

source=Horizon- Trademark Release (March 2016 TSA) (Agreed Form)#page2.tif

source=Horizon- Trademark Release (March 2016 TSA) (Agreed Form)#page3.tif

source=Horizon- Trademark Release (March 2016 TSA) (Agreed Form)#page4.tif

source=Horizon- Trademark Release (March 2016 TSA) (Agreed Form)#page5.tif

## RELEASE OF SECURITY INTEREST IN TRADEMARKS

This RELEASE OF SECURITY INTEREST IN TRADEMARKS (this “Release”), dated as of October 6, 2023 (the “Effective Date”), is made by Citibank, N.A., in its capacity as Administrative Agent and Collateral Agent (the “Agent”), in favor of the grantor party identified on the signature page hereto (the “Grantor”).

WHEREAS, pursuant to that certain U.S. Pledge and Security Agreement, dated as of May 7, 2015, by and among the Agent, the Grantor and certain other parties thereto (as amended, amended and restated, or otherwise modified from time to time, the “Security Agreement”), the Grantor granted to the Agent, in its capacity as Administrative Agent and Collateral Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, the Grantor executed and delivered a Trademark Security Agreement, dated as of March 11, 2016 (the “March 2016 Trademark Security Agreement”), for recordal with the United States Patent and Trademark Office;

WHEREAS, the March 2016 Trademark Security Agreement was recorded with the United States Patent and Trademark Office on September 16, 2016 at Reel/Frame 005879/0196.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:


1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the March 2016 Trademark Security Agreement, as applicable.
2. Release. The Agent, without representation or warranty of any kind, hereby irrevocably releases, discharges, terminates and cancels all of its security interest in all of the Grantor’s right, title and interest, wherever located, in and to: (i) all trademarks (including service marks), trade names, trade styles, trade dress and the registrations and applications for registration thereof that were granted in connection with the March 2016 Trademark Security Agreement, including those listed on Schedule 1 hereto and the goodwill of the business symbolized by the foregoing; (ii) all renewals of the foregoing; (iii) all income, royalties, damages, claims and payments now or hereafter due or payable with respect thereto, including, without limitation, damages, claims, and payments for past and future infringements thereof; (iv) all rights to sue for past, present, and future infringements of the foregoing, including the right to settle suits involving claims and demands for royalties owing; and (v) all rights corresponding to any of the foregoing throughout the world.
3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the March 2016 Trademark Security Agreement.
4. Recordation. The Agent hereby authorizes and requests that the Commissioner for Trademarks of the United States Patent and Trademark Office record this Release.
5. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantor and its successors, assigns or other legal representatives, all such cooperation and assistance (including, without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantor, at the Grantor’s sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

6. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

*[Signature Page Follows]*

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

CITIBANK, N.A., acting in its capacity as  
Administrative Agent and Collateral Agent

By:   
Name: Kevin Ciok  
Title: Vice President

**GRANTOR:**

**HORIZON THERAPEUTICS USA, INC.<sup>1</sup>**

---

<sup>1</sup> NTD: Horizon Pharma Rheumatology LLC merged with and into Horizon Therapeutics USA, Inc.

[Signature Page to Release of March 2016 Trademark Security Agreement]

**TRADEMARK**  
**REEL: 008220 FRAME: 0711**

**SCHEDULE 1**

**TRADEMARKS**

|     | <b>Owner</b>                | <b>Country</b> | <b>Trademark</b>                        | <b>Serial No.<br/>Filing Date</b> | <b>Reg. No.<br/>Reg. Date</b> |
|-----|-----------------------------|----------------|-----------------------------------------|-----------------------------------|-------------------------------|
| 1.  | Crealta Pharmaceuticals LLC | US             | CREALTA                                 | 86/977046<br>9/18/2013            | 4833793<br>10/13/2015         |
| 2.  | Crealta Pharmaceuticals LLC | US             | CREALTA                                 | 86/067833<br>9/18/2013            |                               |
| 3.  | Crealta Pharmaceuticals LLC | US             | CREALTA PHARMACEUTICALS                 | 86/067863<br>9/18/2013            |                               |
| 4.  | Crealta Pharmaceuticals LLC | US             | CREALTA PHARMACEUTICALS                 | 86/976925<br>9/18/2013            | 4823992<br>9/29/2015          |
| 5.  | Crealta Pharmaceuticals LLC | US             | CREALTA PHARMACEUTICALS<br>(STYLIZED)   |                                   |                               |
| 6.  | Crealta Pharmaceuticals LLC | US             | CREALTA PHARMACEUTICALS AND C<br>DESIGN |                                   |                               |
| 7.  | Crealta Pharmaceuticals LLC | AR             | KRYSTEXXA                               | 3126226<br>11/2/2011              | 2726635<br>5/15/2015          |
| 8.  | Crealta Pharmaceuticals LLC | AU             | KRYSTEXXA                               | 1285184<br>2/16/2009              | 1285184<br>2/16/2009          |
| 9.  | Crealta Pharmaceuticals LLC | BR             | KRYSTEXXA                               | 830193189<br>2/17/2009            | 830193189<br>2/7/2012         |
| 10. | Crealta Pharmaceuticals LLC | CA             | KRYSTEXXA                               | 1428115<br>2/17/2009              |                               |
| 11. | Crealta Pharmaceuticals LLC | CN             | KRYSTEXXA                               | 7209501<br>2/20/2009              | 7209501<br>8/21/2010          |
| 12. | Crealta Pharmaceuticals LLC | HK             | KRYSTEXXA                               | 301287469<br>2/16/2009            | 301287469<br>2/16/2009        |
| 13. | Crealta Pharmaceuticals LLC | IN             | KRYSTEXXA                               | 1787489<br>2/19/2009              | 1787489<br>12/6/2012          |
| 14. | Crealta Pharmaceuticals LLC | IL             | KRYSTEXXA                               | 239854<br>8/10/2011               | 239854<br>12/4/2012           |
| 15. | Crealta Pharmaceuticals LLC | JP             | KRYSTEXXA                               | 2009-011005<br>2/18/2009          | 5280562<br>11/13/2009         |
| 16. | Crealta Pharmaceuticals LLC | KR             | KRYSTEXXA                               | 40-2009-<br>0007322<br>2/18/2009  | 799893<br>9/3/2009            |
| 17. | Crealta Pharmaceuticals LLC | LI             | KRYSTEXXA                               | 2011-883<br>9/21/2011             | 16178<br>9/21/2011            |
| 18. | Crealta Pharmaceuticals LLC | MX             | KRYSTEXXA                               | 990227<br>2/17/2009               | 1093461<br>4/7/2009           |
| 19. | Crealta Pharmaceuticals LLC | MC             | KRYSTEXXA                               | 30233<br>6/3/2011                 | 11.28612<br>7/8/2011          |

|     |                             |    |           |                                |                                |
|-----|-----------------------------|----|-----------|--------------------------------|--------------------------------|
| 20. | Crealta Pharmaceuticals LLC | NZ | KRYSTEXXA | 802548<br>2/16/2009            | 802548<br>8/20/2009            |
| 21. | Crealta Pharmaceuticals LLC | PH | KRYSTEXXA | 4-2011-<br>011644<br>9/28/2011 | 4-2011-<br>011644<br>3/29/2012 |
| 22. | Crealta Pharmaceuticals LLC | RU | KRYSTEXXA | 2009703192<br>2/19/2009        | 404873<br>3/29/2010            |
| 23. | Crealta Pharmaceuticals LLC | ZA | KRYSTEXXA | 2011/19724<br>8/11/2011        | 2011/19724<br>10/25/2013       |
| 24. | Crealta Pharmaceuticals LLC | CH | KRYSTEXXA | 59558/2011<br>8/22/2011        | 624135<br>12/23/2011           |
| 25. | Crealta Pharmaceuticals LLC | SG | KRYSTEXXA | T0901651F<br>2/18/2009         | T0901651F<br>2/18/2009         |
| 26. | Crealta Pharmaceuticals LLC | TW | KRYSTEXXA | 099007982<br>2/23/2010         | 1429142<br>9/16/2010           |
| 27. | Crealta Pharmaceuticals LLC | US | KRYSTEXXA | 77/552,516<br>8/21/2008        | 3920201<br>2/15/2011           |
| 28. | Crealta Pharmaceuticals LLC | EM | KRYSTEXXA | 008110967<br>2/18/2009         | 008110967<br>10/7/2009         |
| 29. | Crealta Pharmaceuticals LLC | US | MIGERGOT  | 73/720378<br>4/4/1988          | 1508914<br>10/18/1988          |